Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Analysis of assay used in IMpassion130 to guide treatment of metastatic and advanced breast cancers

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 31.10.19
Views: 742

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

Prof Sherene Loi speaks to ecancer at ESMO 2019 in Barcelona commenting on the post-hoc analysis of the IMpassion130 trial.  

The IMpassion130 trial found that PD-L1 positive patients with advanced or metastatic breast cancer benefitted from the addition of atezolizumab to their treatment.

However, Prof Loi explains that the issue with PD-L1 testing is that there are lots of assays that could be used to determine whether a patient is PD-L1 positive. The post-hoc analysis aimed to understand how different assays compared to the currently approved SP142.

Prof Loi discusses how SP142 compared with SP263 and SP223C and how these insights may impact clinical practice.

Related videos

follow us

Biosimilar Medicines Core Principles and Communication

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation